Circulating Levels of Proprotein Convertase Subtilisin/kexin Type 9 (pcsk9) are Associated With Monocyte Subsets in Patients With Stable Coronary Artery Disease

被引：0
|
作者：
Krychtiuk, Konstantin
Lenz, Max
Hohensinner, Philipp
Distelmaier, Klaus
Schrutka, Lore
Kastl, Stefan
Pfaffenberger, Stefan
Huber, Kurt
Hengstenberg, Christian
Wojta, Johann
Speidl, Walter S.
机构：
来源：
CIRCULATION | 2020年 / 142卷
关键词：
D O I：
10.1161/circ.142.suppl_3.15930
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A15930
引用
收藏
页数：2
相关论文
共 50 条
  • [41] PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS/LUPUS NEPHRITIS
    Fang, C.
    Luo, T.
    Lin, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1768 - 1769
  • [42] The role of proprotein convertase subtilisin kexin 9 (PCSK9) in preeclampsia with severe features
    Bishop, Juliet
    Shaddeau, Angela
    Darwin, Kristin C.
    Wilson, Tenisha
    Boyer, Theresa
    Debrosse, Alexia
    Sharma, Garima
    Vaidya, Dhananjay
    Ouyang, Pamela
    Mukherjee, Monica
    Zakaria, Sammy
    Leucker, Thorsten
    Vaught, Arthur J.
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2020, 222 (01) : S546 - S547
  • [43] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in patients with end-stage renal disease
    Auer, Johann
    Auer, Lisa
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2024, 54 (09)
  • [44] Variations of the proprotein convertase subtilisin/kexin type 9 gene in coronary artery disease
    Chiang, Shih-Min
    Yang, Yi-Sun
    Yang, Shun-Fa
    Tsai, Chin-Feng
    Ueng, Kwo-Chnag
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (01)
  • [45] Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention
    Zhu, Yiming M.
    Anderson, Todd J.
    Sikdar, Khokan
    Fung, Marinda
    McQueen, Matthew J.
    Lonn, Eva M.
    Verma, Subodh
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2015, 35 (10) : 2254 - 2259
  • [46] Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
    Metkus, Thomas S.
    Kim, Bo Soo
    Jones, Steven R.
    Martin, Seth S.
    Schulman, Steven P.
    Leucker, Thorsten M.
    [J]. FRONTIERS IN MEDICINE, 2022, 9
  • [47] Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes
    Trico, Domenico
    Raggi, Francesco
    Distaso, Mariarosaria
    Ferrannini, Ele
    Solini, Anna
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 190
  • [48] Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
    Sun, Huimin
    Meng, Wen
    Zhu, Jie
    Wang, Lu
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2022, 395 (06) : 643 - 658
  • [49] IDENTIFICATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FROM NATURAL PRODUCTS
    Hirata, Hiroshi
    Kontani, Ami
    Takazumi, Koji
    Segawa, Shuichi
    Tsuchiya, Youichi
    [J]. ANNALS OF NUTRITION AND METABOLISM, 2017, 71 : 1175 - 1175
  • [50] Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke
    Zhang, Lingling
    Song, Kangping
    Zhu, Mengting
    Shi, Jinling
    Zhang, Huijuan
    Xu, Liang
    Chen, Yingzhu
    [J]. INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2016, 126 (08) : 675 - 680
12345